RKLB Outperforms Industry in the Past Month: Time to Buy the Stock?

Rocket Lab shares have rallied 66.9% over the past month, outpacing peers and the S&P 500 amid operational milestones including its 21st Electron launch and an $816 million U.S. Space Development Agency award to design and build 18 missile-tracking satellites. Analysts project 2026 revenue growth of ~42.2% year-over-year and upward earnings revisions, but the company trades at a premium (forward P/S 53.41x vs industry 12.32x), reported a 45.6% rise in operating expenses year-to-date through nine months of 2025, and remains loss-making, with a strong liquidity buffer (current ratio 3.18); Zacks assigns a Rank 3 (Hold) and recommends awaiting a better entry point.

Analysis

Market structure: Rocket Lab (RKLB) benefits most from a surge in commercial and national-security small-sat demand (SDA $816M award, 18 sats) and demonstrated launch cadence (21 Electrons/year), lifting suppliers (engines, avionics) and launch-insurance brokers. Competitors with lower-cost production or existing defense relationships (KTOS, AVAV) gain pricing leverage if RKLB must undercut for backlog; legacy GEO rocket providers are less affected. Cross-asset: equity implied volatility in RKLB is likely elevated; a material equity raise would widen high-yield aerospace credit spreads and put pressure on convertible bonds; commodities/FX impact is minimal.

Risk assessment: Tail risks include launch failure, Neutron development cost overruns, milestone-based SDA payments, ITAR/regulatory export limits, and an equity raise that dilutes shareholders. Immediate (days) — elevated volatility and potential mean reversion; short-term (weeks–months) — earnings and contract milestone updates drive moves; long-term (12–36 months) — Neutron commercialization and satellite production margins determine profitability. Hidden dependencies: single-source suppliers, insurance capacity, and milestone-tied revenue recognition.

Trade implications: Prefer small, staged exposure to RKLB (size 1–3% of portfolio) only on 20–30% pullback or confirmed 12+ month runway; favor KTOS/AVAV as lower-P/S defensive longs (2–4% positions). Implement a dollar-neutral pair trade (long KTOS or AVAV, short RKLB) over 3–9 months to capture valuation mean reversion. Use options: buy 3–6 month put spreads on RKLB for 10–20% downside protection or sell 3-month 10% OTM covered calls to monetize long positions.

Contrarian angle: The market is pricing RKLB as if SDA contract revenue is guaranteed and Neutron execution risk is low — P/S F12M ~53x vs peers ~9–12x suggests overreaction. Historical small-cap aerospace rallies often retraced 30–60% after runs and equity raises; if RKLB issues >$250M equity or misses SDA milestones, prepare for sharp downside. A sustained path to positive free cash flow or successful Neutron test would justify premium; until then, premium looks vulnerable.

Key Decisions for Investors

• Establish a staged long RKLB position totaling 1–2% of portfolio: buy 0.5% now, add up to 1.5% only if stock retraces ~25% or management confirms cash runway ≥12 months after the next quarterly report; place a hard stop-loss at -20% vs last tranche entry.
• Initiate a 2–3% long in KTOS (or split between KTOS and AVAV) for lower-valuation defense exposure; consider buying 9–12 month 15–20% OTM call spreads instead of outright equity to limit capital and downside over a 6–12 month horizon.
• Implement a dollar-neutral pair trade: long $1 of KTOS (or AVAV) vs short $1 of RKLB, size 1–2% net exposure, horizon 3–9 months to capture P/S multiple compression; cover if RKLB outperforms by >30% absent clear earnings improvement.
• Hedge existing RKLB exposure with a 3–6 month put spread (buy ~20% OTM put, sell ~35% OTM put) or sell 3-month 10% OTM covered calls to collect premium; adjust hedges if implied vol spikes >50% or if management announces >$250M equity raise.
• Monitor within 30–90 days: (a) SDA milestone/payment schedule and any announced deliveries, (b) quarterly cash burn and operating-expense trend (watch for OPEX growth >40% y/y continuing), and (c) any equity issuance >$250M—reduce RKLB exposure by 50% immediately if any of these signals are triggered.